The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia

Effects of n-3 Polyunsaturated Fatty Acid Therapy on Plasma Inflammatory Markers and N-Terminal Pro-brain Natriuretic Peptide in Elderly Patients with Chronic Heart Failure

(2013) YT Zhao et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Monocyte-Suppressing Effect of Bezafibrate but not Omega-3 Fatty Acids in Patients with Isolated Hypertriglyceridaemia

(2011) Robert Krysiak et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

High Doses of Rosuvastatin are Superior to Low Doses of Rosuvastatin Plus Fenofibrate or n-3 Fatty Acids in Mixed Dyslipidemia

(2011) A. P. Agouridis et al.   LIPIDS

Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants

(2010) Yan Dong et al.   ATHEROSCLEROSIS

Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters

(2010) Ioannis K. Karalis et al.   CURRENT MEDICAL RESEARCH AND OPINION

F2-isoprostanes as an indicator and risk factor for coronary heart disease

(2010) Sean S. Davies et al.   FREE RADICAL BIOLOGY AND MEDICINE

Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome

(2010) Renata Belfort et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of Omega-3 Fatty Acids on Plasma Level of 8-Isoprostane in Kidney Transplant Patients

(2010) Mohammad Ramezani et al.   JOURNAL OF RENAL NUTRITION

Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

(2010)   LANCET

Τhe role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma

(2009) Constantinos C. Tellis et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients

(2009) Giuseppe Derosa et al.   CURRENT MEDICAL RESEARCH AND OPINION

Recent Advances on the Antiatherogenic Effects of HDL-Derived Proteins and Mimetic Peptides

(2009) Maria Petraki et al.   CURRENT PHARMACEUTICAL DESIGN

Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus

(2009) R. P. F. Dullaart et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

(2009) Paul M Ridker et al.   LANCET

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

(2009)   LANCET

The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults

(2008) Maria Weinkouff Pedersen et al.   EUROPEAN JOURNAL OF NUTRITION

An Overview of the Extra-Lipid Effects of Rosuvastatin

(2008) Michael S. Kostapanos et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS